879014-19-4

Usage

Derivative of imidazole

A five-membered heterocyclic compound containing nitrogen

Acetonitrile group

A cyano group attached to an imidazole ring

Phenylmethyl substituent

A phenyl group attached to a methyl group, which is attached to the imidazole ring

Versatile intermediate compound

Can be used to synthesize a variety of other compounds

Building block in organic synthesis

Used as a starting material in the synthesis of pharmaceuticals and agrochemicals

Potential applications in drug development

May be used to create new drug molecules

Unique chemical properties

Allows for the creation of diverse molecular structures

Great potential for further research and development

In the field of organic chemistry

Upstream product

• 105-56-6 ethyl 2-cyanoacetate 
• 4152-09-4 N-benzylethylenediamine 

Relevant academic research and scientific papers

PHOSPHODIESTERASE 10 INHIBITORS

Provided are certain quinazolines of formular (I) or (II) that are PDElO inhibitors, pharmaceutical compositions, containing the same and processes for preparing the same. Also provided are methods of treating diseases treatable by PDElO enzyme such as ob

4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS

The present disclosure relates generally to the field of phosphodiesterase 10 (PDE10) enzyme inhibition by cinnoline compounds of Formulas: (I) and (II); wherein R'-R3 and R15-R18 are as defined herein. Still further, the present invention provides methods for synthesizing compounds with such activity and selectivity, as well as methods of and corresponding pharmaceutical compositions for treating a patient, e.g., mammals, including humans, in need of PDE inhibition. Treatment is preferably for a disease state that involves elevated intracellular PDE10 levels or decreased cAMP and/or cGMP levels, e.g., involving neurological or psychiatric syndromes, especially those states associated with psychoses, most especially schizophrenia or bipolar disorder, obsessive-compulsive disorder, and/or Parkinson’s disease. In particular, such psychoses, obsessive-compulsive disorder, and/or Parkinson’s disease are due at least in part to catabolism of intracellular cAMP and/or cGMP levels by PDE10 enzymes or where such an impaired condition can be improved by increasing cAMP and/or cGMP levels.